Table 1 Demographic and clinical characteristics
|  | CLV group (n = 77) | RALV group (n = 32) | χ2/t/z | P value |
|---|---|---|---|---|
Age, years | 54.9 ± 9.0 | 56.0 ± 6.5 | -0.627 | 0.532 |
BMI, kg/m2 | 23.9 ± 1.8 | 24.1 ± 2.0 | -0.536 | 0.593 |
ASA grade | Â | Â | 1.448 | 0.229 |
 I | 57 (74.0) | 20 (62.5) |  |  |
 II | 20 (26.0) | 12 (37.5) |  |  |
Menopause | Â | Â | 0.472 | 0.492 |
 Yes | 67 (87.0) | 30 (93.8) |  |  |
 No | 10 (13.0) | 2 (6.3) |  |  |
Infection with high-risk HPV | Â | Â | 0.252 | 0.969 |
 HPV16 | 46 (59.7) | 20 (62.5) |  |  |
 HPV18 | 5 (6.5) | 2 (6.3) |  |  |
 Other high-risk HPV | 19 (24.7) | 8 (25.0) |  |  |
 Unknown/none | 7 (9.1) | 2 (6.3) |  |  |
Antecedent cytology at diagnosis | Â | Â | 3.389 | 0.495 |
 ASC-US | 17 (22.1) | 10 (31.3) |  |  |
 ASC-H | 9 (11.7) | 3 (9.4) |  |  |
 LSIL | 15 (19.5) | 3 (9.4) |  |  |
 HSIL | 19 (24.7) | 6 (18.8) |  |  |
 Unknown/none | 17 (22.1) | 10 (31.3) |  |  |
Vaginal estrogen pretreatment | Â | Â | 2.427 | 0.119 |
 Yes | 24 (31.2) | 15 (46.9) |  |  |
 No | 53 (68.8) | 17 (53.1) |  |  |
Clinical symptoms | Â | Â | 1.446 | 0.485 |
 Symptom-free | 54 (70.1) | 26 (81.3) |  |  |
 Abnormal vaginal  secretions | 16 (20.8) | 4 (12.5) |  |  |
 Bleeding after  sexual intercourse | 7 (9.1) | 2 (6.3) |  |  |
Diabetes |  |  | < 0.001 | > 0.999 |
 Yes | 9 (11.7) | 4 (12.5) |  |  |
 No | 68 (88.3) | 28 (87.5) |  |  |
Range of vaginal HSIL |  |  | > 0.999 | < 0.001 |
 ≤upper third of vagina | 43 (55.8) | 6 (18.8) |  |  |
 >upper third of vagina | 34 (44.2) | 26 (81.3) |  |  |
Previous hysterectomy | 32 (41.6) | 11 (34.4) | 0.488 | 0.485 |
 Indication for  hysterectomy (n = 43) |  |  | 0.166 | 0.684 |
  Cervical HSIL | 27 (84.4) | 8 (72.7) |  |  |
  Benign disease | 5 (15.6) | 3 (27.3) |  |  |
Treatment of vaginal HSIL before vaginectomy | Â | Â | 0.257 | 0.879 |
 Photodynamic therapy | 7 (9.1) | 2 (6.3) |  |  |
 Laser ablation | 2 (2.6) | 1 (3.1) |  |  |
 None detection | 68 (88.3) | 29 (90.6) |  |  |